Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson's Disease in Addition to Amyotrophic Lateral Sclerosis -January 16, 2024 at 08:16 am EST
All three conditions share common hallmark of complex inflammatory pathways underlying disease pathophysiology that involve dysfunctional regulatory T cell biology which may limit efficacy of...
Source: marketscreener.com